Evaluation Study of Retro Discal Tissue Injection Arthroscopically Versus Ultrasound Guide Injection
Condition(s) studied
Investigational drug(s) / intervention(s)
Arthroscopic retrodiscal tissue injection: Arthroscopic retrodiscal tissue injection
Ultrasound-guided retrodiscal tissue injection: Ultrasound-guided retrodiscal tissue injection
Study summary
A comparative evaluation study of arthroscopic retrodiscal tissue injection versus ultrasound-guided injection in temporomandibular joint disorders aims to assess differences in pain relief, functional improvement, and clinical outcomes between an invasive and a minimally invasive delivery technique. Arthroscopic injection allows direct visualization of intra-articular structures, accurate targeting of the retrodiscal tissues, and simultaneous management of associated pathology such as synovitis or adhesions, which may enhance therapeutic outcomes in advanced internal derangement. In contrast, ultrasound-guided injection offers a less invasive, cost-effective, and outpatient-based approach with improved accuracy over blind techniques, making it suitable for early or moderate cases. While both methods are effective in reducing pain and improving mouth opening and jaw function, arthroscopic injection may provide superior results in patients requiring diagnostic confirmation and mechanical intervention, whereas ultrasound-guided injection offers comparable symptomatic improvement with lower procedural morbidity and resource utilization.
Eligibility
Primary outcome measure(s)
- Pain intensity (VAS) — Baseline → 2 months (early outcome) Baseline → 6 months (mid-term outcome)
Change in TMJ pain score measured on a 10-cm Visual Analogue Scale (0 = no pain, 10 = worst pain) from baseline to 3 months post-intervention.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| facility of Dentistry | Cairo | Old Cairo |
More Cairo University trials in Egypt
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07316790 on ClinicalTrials.gov ↗ ← All trials in Egypt